{"type":"trials","record":{"id":41415,"source_id":"clinicaltrials-gov","external_id":"NCT06087458","title":"Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration","brief_summary":"The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.","overall_status":"Active Not Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Perceive Biotherapeutics, Inc.","enrollment":60,"countries":["United States","Australia","Israel"],"start_date":"2023-06-21","completion_date":"2028-06-01","last_update_date":"2026-08-17","source_url":"https://clinicaltrials.gov/study/NCT06087458","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"JOURNEY","age_range":"60 Years","comparator":null,"organization":"Perceive Biotherapeutics, Inc.","interventions":["VOY-101"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101 — 24…","Phase 1: Change from Baseline in markers of inflammation — Baseline to Month 24","Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy. — Month 12","Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic…","Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors — Baseline through 24 M…","Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101. — Baseline through 24 Months","Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity — 24 Months","Phase 1/2: Development of macular neovascularization — Month 24","Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101 — 24 Months","Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy le…","Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity — Baseline through Month 24"],"design_description":"RANDOMIZED · SINGLE GROUP · TREATMENT · SINGLE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Geographic Atrophy","Non-neovascular AMD","Non-neovascular Age-related Macular Degeneration","VOY-101"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06087458","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-06-21 to 2028-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.808Z","intervention":["VOY-101"],"participants":60,"study_design":"RANDOMIZED · SINGLE GROUP · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101 — 24…","Phase 1: Change from Baseline in markers of inflammation — Baseline to Month 24","Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy. — Month 12","Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic…","Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors — Baseline through 24 M…","Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101. — Baseline through 24 Months","Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity — 24 Months","Phase 1/2: Development of macular neovascularization — Month 24","Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101 — 24 Months","Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy le…","Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity — Baseline through Month 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41415","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}